Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
In BriefThis Month in JNM

This Month in JNM

Journal of Nuclear Medicine May 2017, 58 (5) 9A;
  • Article
  • Info & Metrics
  • PDF
Loading

68Ga vs. 18F in prostate cancer: Kesch and colleagues look at the clinical and logistic advantages of prostate-specific membrane antigen agents labeled with these 2 common tracers in patients with prostate cancer.

Page 687

PET, preclinical imaging, and optimal care: Clark and colleagues provide an overview of the underlying biochemical and biologic bases for a variety of PET tracers and discuss their potential in research to advance personalized cancer therapy.

Page 689

Prescribed activity of 131I: Van Nostrand offers commentary and perspective on the need for critical scrutiny of published evidence on selection of activity for 131I therapy in patients with well-differentiated thyroid cancer.

Page 697

Bevacizumab and 18F-FET uptake: Stegmayr and colleagues investigate the effects of bevacizumab on blood–brain barrier permeability and 18F-FET uptake on PET in a human xenograft model as a possible solution to confounding posttreatment pseudoresponses on MR imaging.

Page 700

Targeted imaging of micrometastases: Hekman and colleagues assess whether dual-modality imaging using a humanized anticarcinoembryonic antigen monoclonal antibody labeled with 111In-DTPA and a near-infrared fluorescent dye can detect pulmonary micrometastases in a mouse model.

Page 706

89Zr-bevacizumab PET in DIPGs: Jansen and colleagues determine the ability of bevacizumab to reach tumors in children with diffuse intrinsic pontine gliomas by measuring 89Zr-labeled bevacizumab uptake on PET, with additional data on safety and optimal imaging timing.

Page 711

RAI and metastatic thyroid cancer: Deandreis and colleagues compare empiric and whole-body/blood clearance dosimetry–based approaches to radioactive iodine treatment in patients with metastases from differentiated thyroid cancer.

Page 717

Response prediction in esophageal cancer: Beukinga and colleagues report on a model designed to predict complete tumor response to neoadjuvant chemoradiotherapy in esophageal cancer based on pretreatment clinical parameters and 18F-FDG PET/CT–derived textural features.

Page 723

Predictive PET in HCC: Na and colleagues describe the prognostic value of 18F-FDG uptake on PET/CT at time of presentation in patients with Barcelona Clinic Liver Cancer stage C hepatocellular cancer.

Page 730

Follow-up PET/CT in oncology: Taghipour and colleagues explore retrospective data on common clinical indications for performing 4 or more follow-up 18F-FDG PET/CT scans and on resulting effects in patient management.

Page 737

Validation of Ki images: Ilan and colleagues evaluate parametric methods for computation of net influx rate in somatostatin analog imaging by comparison with volume-of-interest–based methods and assess image contrast in terms of tumor-to-liver ratio.

Page 744

Late PET/CT with 68Ga-PSMA-11: Afshar-Oromieh and colleagues assess effects on tumor detection and clinical impact of PET/CT imaging acquired 3 hours after injection of this small-molecule inhibitor of prostate-specific membrane antigen in patients with prostate cancer.

Page 750

SSTR PET/CT management: Barrio and colleagues detail the results of a systematic review and meta-analysis to evaluate the impact of somatostatin receptor PET/CT on management of patients with neuroendocrine tumors.

Page 756

Mapping A2AR with 11C-preladenant: Zhou and colleagues explore the suitability of 11C-preladenant PET imaging for quantification of striatal adenosine A2A receptors and assessment of receptor occupancy in conscious rhesus monkeys.

Page 762

Quantification of diaschisis: Segtnan and colleagues use 18F-FDG PET/CT to investigate the prognostic implications of total hemispheric glucose metabolism ratio in cerebrocerebellar diaschisis in patients with supratentorial gliomas.

Page 768

PET/CT and vulnerable plaques: Wan and colleagues quantify 68Ga-DOTATATE uptake in carotid plaque in patients with recent carotid events, assess inter- and intraobserver variability, and describe associated immunohistochemical markers.

Page 774

Sympathetic imaging in HFpEF: Boutagy and Sinusas offer perspective on the potential of radionuclide-based imaging of the cardiac sympathetic nervous system in patients with heart failure with preserved ejection fraction and preview a related article in this issue of JNM.

Page 781

11C-hydroxyephedrine PET in HFpEF: Aikawa and colleagues detail the relationship between myocardial sympathetic innervation quantified by 11C-hydroxyephedrine PET and diastolic dysfunction in patients with heart failure with preserved ejection fraction.

Page 784

Assessing cyclotron-produced 99mTc: Selivanova and colleagues report on a prospective clinical study with cyclotron-produced 99mTc-sodium pertechnetate in patients with indications for thyroid scanning to demonstrate safety and efficacy and to compare with conventional generator-eluted 99mTc-NaTcO4.

Page 791

Sympathetic innervation of BAT and WAT: Muzik and colleagues use 11C-HED, 15O-water, and 18F-FDG PET to explore the relationship between sympathetic innervation and cold-induced activation of brown and white adipose tissue in lean young adults.

Page 799

Optoacoustic tomography precision: Joseph and colleagues use phantoms and mice to assess the repeatability and reproducibility of a commercial small-animal optoacoustic tomography system and discuss the implications for reliable longitudinal imaging.

Page 807

2-18F-FEtOH as a perfusion reporter: Wadsworth and colleagues describe investigation of 2-18F-fluoroethanol PET in differentiation between tumors of varying perfusion levels, with potential applications in screening drugs that modify tumor perfusion.

Page 815

HER2-targeting peptide probe: Li and colleagues detail the development and preclinical evaluation of 99mTc-HYNIC-H6F, a human epidermal growth factor receptor 2–targeted peptide probe for SPECT imaging in breast cancer.

Page 821

11C-methoxybenzamide PET in melanoma: Garg and colleagues report on synthesis and preclinical assessment of this11C-labeled probe for selectively targeting melanoma using PET.

Page 827

4D MR and attenuation map generation: Fayad and colleagues investigate the generation of 4D MR images and associated attenuation maps from a single static MR image combined with motion fields obtained from simultaneously acquired 4D non–attenuation-corrected PET images.

Page 833

PET/MR implant AC: Fuin and colleagues present a novel technique for accurate whole-body attenuation correction in the presence of metallic endoprostheses on integrated non–time-of-flight PET/MR scanners.

Page 840

Motion correction for cardiac PET/MR: Kolbitsch and colleagues investigate a new cardiac PET/MR approach providing respiratory and cardiac motion-compensated MR and PET images in less than 5 minutes.

Page 846

In vivo hypoxia imaging in RA: Fuchs and colleagues measure hypoxia noninvasively in arthritic ankles with 18F-FMISO and 18F-FAZA PET/MR and quantify temporal and other dynamics of hypoxia and reactive oxygen species stress with a chemiluminescent optical imaging probe.

Page 853

  • © 2017 by the Society of Nuclear Medicine and Molecular Imaging.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 58 (5)
Journal of Nuclear Medicine
Vol. 58, Issue 5
May 1, 2017
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
This Month in JNM
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
This Month in JNM
Journal of Nuclear Medicine May 2017, 58 (5) 9A;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
This Month in JNM
Journal of Nuclear Medicine May 2017, 58 (5) 9A;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • Sympathetic Innervation of Cold-Activated Brown and White Fat in Lean Young Adults
  • PET/MRI in the Presence of Metal Implants: Completion of the Attenuation Map from PET Emission Data
  • Prescribed Activity of 131I Therapy in Differentiated Thyroid Cancer
  • 18F-FDG PET/CT Can Predict Survival of Advanced Hepatocellular Carcinoma Patients: A Multicenter Retrospective Cohort Study
  • Predicting Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer with Textural Features Derived from Pretreatment 18F-FDG PET/CT Imaging
  • Evaluation of Precision in Optoacoustic Tomography for Preclinical Imaging in Living Subjects
  • Detection of Micrometastases Using SPECT/Fluorescence Dual-Modality Imaging in a CEA-Expressing Tumor Model
  • Parametric Net Influx Rate Images of 68Ga-DOTATOC and 68Ga-DOTATATE: Quantitative Accuracy and Improved Image Contrast
  • Clinical Indications and Impact on Management: Fourth and Subsequent Posttherapy Follow-up 18F-FDG PET/CT Scans in Oncology Patients
  • 68Ga or 18F for Prostate Cancer Imaging?
  • 4-Dimensional MRI and Attenuation Map Generation in PET/MRI with 4-Dimensional PET-Derived Deformation Matrices: Study of Feasibility for Lung Cancer Applications
  • Prognostic Implications of Total Hemispheric Glucose Metabolism Ratio in Cerebrocerebellar Diaschisis
  • Comparison of Empiric Versus Whole-Body/-Blood Clearance Dosimetry–Based Approach to Radioactive Iodine Treatment in Patients with Metastases from Differentiated Thyroid Cancer
  • Imaging of the Cardiac Sympathetic Nervous System Has Potential Value in the Evaluation of Patients with Heart Failure with Preserved Ejection Fraction
  • In Vivo Evaluation of 11C-Preladenant for PET Imaging of Adenosine A2A Receptors in the Conscious Monkey
  • PET/CT Imaging of Unstable Carotid Plaque with 68Ga-Labeled Somatostatin Receptor Ligand
  • The Impact of Somatostatin Receptor–Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis
  • Cardiac and Respiratory Motion Correction for Simultaneous Cardiac PET/MR
  • Molecular Drug Imaging: 89Zr-Bevacizumab PET in Children with Diffuse Intrinsic Pontine Glioma
  • Influence of Bevacizumab on Blood–Brain Barrier Permeability and O-(2-18F-Fluoroethyl)-l-Tyrosine Uptake in Rat Gliomas
  • In Vivo Hypoxia PET Imaging Quantifies the Severity of Arthritic Joint Inflammation in Line with Overexpression of Hypoxia-Inducible Factor and Enhanced Reactive Oxygen Species Generation
  • 4-11C-Methoxy N-(2-Diethylaminoethyl) Benzamide: A Novel Probe to Selectively Target Melanoma
  • Clinical Trial with Sodium 99mTc-Pertechnetate Produced by a Medium-Energy Cyclotron: Biodistribution and Safety Assessment in Patients with Abnormal Thyroid Function
  • 2-18F-Fluoroethanol Is a PET Reporter of Solid Tumor Perfusion
  • Harnessing Preclinical Molecular Imaging to Inform Advances in Personalized Cancer Medicine
  • Impaired Myocardial Sympathetic Innervation Is Associated with Diastolic Dysfunction in Heart Failure with Preserved Ejection Fraction: 11C-Hydroxyephedrine PET Study
  • SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe 99mTc-HYNIC-H6F in Breast Cancer Mouse Models
  • The Clinical Impact of Additional Late PET/CT Imaging with 68Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate Cancer
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • This Month in JNM
  • This Month in JNM
  • This Month in JNM
Show more This Month in JNM

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire